Vancouver, British Columbia – TheNewswire – December 16, 2020 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) US (OTC:BLRZF) (the “Company“), is pleased to announce that one of its portfolio companies, Trip Pharma Inc. (“Trip Pharma“), a mental health and wellness company focused on the production of psychedelics and psychedelic-enhanced psychotherapy, will be opening its first medical center in Edmonton, Alberta specializing in the administration of holistic and psychedelic-enhanced psychotherapy.

The center will be branded LeichtMind (pronounced “light mind”) and is scheduled to open its doors in early Q1 2021. The goal of this center is to provide a much-needed safe community and space for patients seeking out specific revolutionary treatments, allowing them to access Trip Pharma’s proprietary produced medications and compounds.

Led by Dr. Krista Leicht, this purpose-built psychiatric clinic will provide patients with best-in-class care and complementary treatments while providing a welcoming and stigma-free environment. Dr. Leicht will be joined by a team of like-minded Psychiatrists, Psychologists and Medical Practitioners whose aim is to combat the mental health crisis facing Canada and using telemedicine to potentially reach anyone in the world.

“Leading research institutions like Johns Hopkins University and New York University have presented the positive effects of psychedelic-enhanced psychotherapy” said Frederick Pels, CEO of Blackhawk Growth Corp. “It is truly amazing to be involved with such a forward-thinking team that we have assembled in Trip Pharma and LeichtMind. As LeichtMind becomes a leader and facilitator of the profound, sustainable results that these treatments can provide, growth is inevitable. I look forward to updating our shareholders on these initiatives in the near future.”

As part of our goal to expand the possible treatment options in the clinic, Trip Pharma has begun the process of completing an application for a controlled drugs and substances dealers licence in Canada.  The company is working to source a library of psilocybin cubensis genetics that will provide a supply of high-quality products for use in research and prescription for clinical patients.

Once the clinic is fully operational, it is the Company’s intention to have Blackhawk’s 100% owned telemedicine platform – “Talk to Doc” be the exclusive provider for patients to connect to medical professionals virtually at LeichtMind.


About Dr. Krista Leicht

Dr. Leicht is a Canadian-trained and Alberta-licensed medical doctor and psychiatrist, who brings over 20 years of clinical experience to the team. She has divided her time in a busy practice between inpatient and outpatient care, treating both the general adult psychiatry population and specializing in addressing the complex needs of developmentally handicapped individuals. Dr. Leicht maintains a hospital practice at Alberta Hospital Edmonton and sees outpatients in a South Edmonton clinic. She continues to teach medical students, residents and provides further education to family-practice colleagues. Dr. Leicht’s goal in clinical practice and in her own life has always been to go beyond — to provide unique and innovative treatments that better enrich the lives of patients is her mission.

For further information please contact:

Frederick Pels, Chief Executive Officer


This email address is being protected from spambots. You need JavaScript enabled to view it.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to completion of the Transaction and the business activities of Trip Pharma. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.